Fact CheckerSign in

NCT07682935Recruiting

Investigation of the Effects of Angling as Supportive Therapy in Schizophrenia Treatment on Serum Parameters, Anxiety, Depression, and Quality of Life

Angling as a Supportive Therapy in the Treatment of Schizophrenia

Source: ClinicalTrials.gov · Last updated 7 Jul 2026

Brief summary (registry, in English)

This study aims to evaluate the effects of recreational fishing (angling) as a supportive therapeutic intervention in individuals diagnosed with schizophrenia. Schizophrenia is a chronic psychiatric disorder characterized by disturbances in thinking, perception, emotion, and behavior, often accompanied by negative symptoms such as social withdrawal, anhedonia, and cognitive impairment, which significantly reduce quality of life. Recreational activities, particularly those involving nature-based engagement, have been shown to support psychological well-being through stress reduction, improved attention, and enhanced mood regulation. Angling is considered a mindfulness-like recreational activity that promotes relaxation, concentration, and emotional regulation, potentially offering benefits for individuals with psychiatric conditions. In this randomized controlled study, participants with schizophrenia will engage in a structured recreational fishing program in addition to standard care. The effects of the intervention will be evaluated on biochemical serum parameters, anxiety and depression levels, and quality of life outcomes. The study also aims to assess the psychosocial well-being of participants and determine the feasibility of integrating angling as an adjunctive non-pharmacological intervention in schizophrenia care. The findings are expected to contribute to evidence-based complementary treatment approaches in psychiatric rehabilitation.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
60 (estimated)
First submitted
26 Jun 2026
Start date
15 Jun 2026
Primary completion date
15 Jul 2026
Lead sponsor
Firat University
NCT number
NCT07682935

What you commit to

  • Study type: Interventional
  • Planned participants: 60
  • From 15 Jun 2026 to the primary completion date, 15 Jul 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Presence of comorbid psychiatric disorders other than schizophrenia

Other

  • Patients in the acute psychotic (attack) phase

Who the study is looking for

  • Adults aged 18 years and older
  • Able to communicate verbally
  • Diagnosed with schizophrenia
  • Able to provide written informed consent

Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Fırat university
Coordinator of this site? Confirm its status
ElâzığTurkey (Türkiye)Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.